by TractManager | Aug 6, 2024 | Emerging Technology Report
Afamitresgene autoleucel (afami-cel; Adaptimmune LLC) is an intravenously administered melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of select adults with previously treated,...
by TractManager | Aug 5, 2024 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the ReActiv8 Implantable Neurostimulation System for mechanical chronic low back pain due to lumbar multifidus...
by TractManager | Aug 2, 2024 | Emerging Technology Report
INO-3107 (Inovio Pharmaceuticals Inc.) is an injectable plasmid DNA immunotherapy under investigation in combination with electroporation for the treatment of recurrent respiratory papillomatosis in adults.
by TractManager | Aug 2, 2024 | Emerging Technology Report
UX111 (Ultragenyx Pharmaceutical Inc.) is an investigational single-infusion gene therapy proposed for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA).
Recent Comments